Evidence map›Paper›PMID 41182273›Full record

ArticleCurrent protocols2025

Middle-Down Nuclear Magnetic Resonance for Therapeutic Monoclonal Antibody Glycan Profiling.

Jiayi Li, Grace Zhang, Kang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiayi LiDivision of Pharmaceutical Quality Research VI, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Grace ZhangDivision of Pharmaceutical Quality Research VI, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Kang ChenDivision of Pharmaceutical Quality Research VI, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Recombinant monoclonal antibodies (mAbs) are widely used across therapeutic areas, and their glycosylation plays a critical role in product quality, manufacturing consistency, and biosimilarity assessment. A middle-down nuclear magnetic resonance (NMR) method has been developed to profile mAb glycan distribution while preserving the covalent bond between glycan and mAb domains, e.g., the fragment crystallizable (Fc) domain. The workflow uses the immunoglobulin-degrading enzyme from Streptococcus pyogenes (IdeS) to generate Fc fragments that are purified, denatured, and dissolved in urea prior to high-resolution two-dimensional

Indexed as

Antibodies, MonoclonalNuclear Magnetic Resonance, BiomolecularPolysaccharidesGlycosylationHumansImmunoglobulin Fc FragmentsMagnetic Resonance SpectroscopyAntibodies, MonoclonalImmunoglobulin Fc FragmentsPolysaccharidesanomeric peakbiosimilarchemical shiftglycan distributionprofile

Identifiers

PMID41182273
PMCPMC12892841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.